Direct Oral Anticoagulants (DOACs): Current Evidence for Extended VTE Prophylaxis and Reversal
Monday, April 9, 2018 | 7:30pm - 9:30pm
Held in conjunction with Hospital Medicine 2018, SHM’s Annual Conference
Orlando World Center Marriott - Room Canary 3-4
Complimentary dinner provided beginning at 7:30 pm
Patients hospitalized for an acute medical illness are at an increased risk for VTE. With increasingly shortened hospital stays, acutely ill hospitalized patients are at an increased risk of developing VTE both in the hospital and after discharge. Outpatient VTE episodes often occur within 30 days of hospital discharge and less than half of those discharged patients receive VTE prophylaxis. Therefore, it is important for clinicians to be able to risk stratify patients and provide extended prophylaxis for medical patients at increased risk for VTE.
This symposium will discuss the risk factors and burden of VTE and review ACCP guideline recommendations for VTE prophylaxis in acutely ill hospitalized medical patients. Faculty will assess the safety and efficacy of direct oral anticoagulants for extended VTE prophylaxis, explain the stratification of VTE and bleeding risk, as well as the process for devising evidence-based antithrombotic regimens. The presentation will also include an outline of current and emerging options for reversal of direct oral anticoagulants.
- Outline the risk factors and burden of VTE in medically ill patients post-hospitalization
- Review ACCP and ASH guideline recommendations for VTE prophylaxis in acutely ill hospitalized medical patients
- Assess the safety and efficacy of direct oral anticoagulants (DOACs) for extended VTE prophylaxis in medically ill patients
- Devise evidence-based antithrombotic regimens for medically ill patients taking into consideration patient specific factors that impact VTE and bleeding risk
- Outline current and emerging options for reversal of DOACs
Hospitalists, internists, nurse practitioners (NPs), physician assistants (PAs) who practice in a hospital setting.
Horizon CME designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
ABIM MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This activity is supported by an independent educational grant from Portola Pharmaceuticals.
Amir K. Jaffer, MD, MBA
Chief Medical Officer
New York Presbyterian Hospital
Alan K. Jacobson, MD, FACC
Assistant Professor of Medicine
Loma Linda University School of Medicine
Director of Anticoagulation Services
Loma Linda VA Medical Center
Loma Linda, CA
Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC
Professor of Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
System Director – Anticoagulation and Clinical Thrombosis Services
Northwell Health at Lenox Hill Hospital
New York, NY